Celgene Corp. & Sage Bionetworks Announce Technology Collaboration to Develop Observational Study Using the Apple ResearchKit...
October 18 2016 - 7:30AM
Business Wire
Observational study to examine the burden of
chronic anemia in myelodysplastic syndromes and
beta-thalassemia
Celgene Corporation (NASDAQ: CELG) and Sage Bionetworks today
announced a collaboration to develop an iPhone application
utilizing the Apple ResearchKit framework to improve the
understanding of the burden of disease for patients living with
chronic anemia due to myelodysplastic syndromes (MDS) or
beta-thalassemia.
Smartphone-based apps like Sage Bionetworks’ mPower for
Parkinson’s disease are increasingly being utilized as a tool by
clinical study researchers to collect and analyze increasing
volumes of patient-reported data in order to better capture and
understand disease burden better and to improve therapeutic
developments. Smartphone clinical study apps also enable the return
communication of important study information to the patient
participants.
“We stand at a point where technology is unlocking the ability
to capture patient reported outcomes,” said Michael Pehl,
President, Hematology & Oncology for Celgene. “Through our
collaboration with Sage Bionetworks and the evolving capability of
smartphones and wearables as robust data collection devices, we
believe we will be able to provide important new insights for
patients with MDS and beta-thalassemia. We are pleased to be
working alongside Sage Bionetworks and the patient community on
this important project.”
Celgene and Sage Bionetworks have chosen to address chronic
anemia caused by myelodysplastic syndromes and beta-thalassemia.
These diseases impose a great burden on affected individuals that
is difficult to understand and quantify, and typically have
clinical endpoints outside traditional measures. The collaboration
seeks to move to a paradigm where this and other information like
physiological testing are collected on a multi-dimensional and
regular basis.
Already a leader in MDS, Celgene is currently developing three
assets in the clinic across myelodysplastic syndromes and
beta-thalassemia (CC-486, luspatercept, and enasidenib
(AG-221/CC-90007)).
In addition to helping collect difficult to quantify data, the
new mobile study will collect neurological assessments of patients
using cognitive testing software from BrainBaseline, a leading
technology for the self-assessment of cognitive performance. The
app will also be an important channel for two-way communication and
support for patients living with their disease – allowing them to
understand their physical functioning and other symptoms of
anemia.
Dr. Lara Mangravite, President of Sage Bionetworks stated, “We
are thrilled to partner with Celgene to explore the use of
sensor-based technologies to quantify the daily burden of disease
in patients with chronic anemia. This is a first of its kind
exploration from which we hope to gain insights that can be used to
understand the impact of chronic anemia.”
Celgene and Sage Bionetworks are working closely with the MDS
Foundation (www.mds-foundation.org) and Cooleys Anemia Foundation
(www.thalassemai.org) in defining the right elements for capture in
the application to ensure patient relevance and applicability.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey,
is an integrated global biopharmaceutical company engaged primarily
in the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow
Celgene on Social
Media: @Celgene, Pinterest, LinkedIn, FaceBook and YouTube.
About Sage Bionetworks
(www.sagebase.org)
Sage Bionetworks is a nonprofit biomedical research
organization, founded in 2009, with a vision to promote innovations
in personalized medicine by enabling a community-based approach to
scientific inquiries and discoveries. In pursuit of this Mission,
Sage Bionetworks is working with others to assemble an information
Commons for biomedicine that (1) is supported by an open compute
space (Synapse: www.synapse.org), (2) supports open research
collaborations and innovative DREAM Challenges, and (3) empowers
citizens and patients with the tools to partner with researchers
and share their data through Sage’s BRIDGE platform
(http://sagebase.org/bridge/) in order to drive the research
studies that matter most to them.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. Celgene undertakes no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond Celgene’s
control. Actual results or outcomes may differ materially from
those implied by the forward-looking statements as a result of the
impact of a number of factors, many of which are discussed in more
detail in Celgene’s Annual Report on Form 10-K and other reports
filed with the Securities and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161018005868/en/
For
Celgene:Investors:908-673-9628investors@celgene.comorMedia:908-673-2275media@celgene.comorFor
Sage:Media:206-667-3192
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2024 to May 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From May 2023 to May 2024